The uncommon lung condition known as pulmonary alveolar proteinosis (PAP) is characterized by the build-up of aberrant lipids and surfactant proteins alveoli. In tiny lungs air sacs, the gas exchange takes place.
Damage to the alveolar walls and adjacent tissues results from the excess surfactant accumulation causing an inflammatory response within the alveoli.
Gas exchange is hampered in PAP due to an aberrant buildup of surfactant in the alveoli.
Epidemiology
With an approximate yearly incidence of less than 1 case per million people, PAP is regarded as a rare disease.
While PAP can occur anyone at any age, most cases are identified in people between the ages of 20 and 50.
PAP does not seem to have a substantial preference for either gender, affecting both sexes equally.
Location
As a result of the excess surfactant material filling the alveoli, less room is available for gas exchange and air is displaced. This filling causes blood oxygenation to be reduced, which can result in respiratory symptoms as coughing and dyspnea.
Within the alveoli, the accumulation of surfactant causes an inflammatory reaction. Inflammation can worsen gas exchange and is a contributing factor to lung damage.
Prolonged surfactant buildup can cause structural alterations in the alveoli, such as fibrosis and thickening of the alveolar wall. These alterations worsen lung function and add to the disease’s progressive character.
Anatomy
Pathophysiology
Etiology
PAP that is categorized as autoimmune PAP accounts for the majority of instances. The immune system malfunction mainly involving lung macrophages is the root cause of this subtype. Surfactant accumulates in the alveoli of patients with autoimmune PAP due to insufficient clearance caused by malfunctioning or impaired macrophages.
A cytokine called granulocyte-macrophage colony-stimulating factor (GM-CSF) is essential for controlling surfactant clearance and alveolar macrophage activity.
Alveolar macrophage activity and surfactant clearance can be negatively impacted by autoantibodies against GM-CSF or mutations in genes encoding GM-CSF receptor components. These disruptions of normal signalling pathways can also occur.
Genetics
Prognostic Factors
Prognosis and Predictive Factors
Autoimmune PAP tends to have a better prognosis compared to secondary PAP, as autoimmune PAP is typically more responsive to treatment.
Secondary PAP, which occurs in the context of other underlying conditions, may have a less favorable prognosis, particularly if the underlying condition is severe or difficult to treat.
The severity of symptoms at the time of diagnosis can influence prognosis.
Imaging features such as the extent of lung involvement, presence of consolidations, and degree of ground-glass opacities may provide prognostic information.
Elevated levels of anti-GM-CSF antibodies or other serum biomarkers may be associated with more severe disease and poorer prognosis in autoimmune PAP.
Histopathological features observed on lung biopsy, such as the degree of inflammation, fibrosis, and alveolar damage, may provide insights into disease severity and prognosis.
Clinical History
Clinical Features and Imaging
Progressive exertional dyspnea is a frequently encountered sign of postural hypoxia. As the condition progresses, patients may experience breathing difficulties when exercising or even when they are at rest.
Another typical symptom is a persistent cough that frequently produces thick, viscous sputum. PAP patients usually complain of exhaustion and a reduced capacity for activity because of their compromised lung health.
Because of hypoxemia, cyanosis a bluish staining of the skin and mucous membranes may be seen in the disease’s later stages.
Severe PAP episodes may result in respiratory failure necessitating mechanical ventilation or further oxygen therapy.
Imaging Findings:
Bilateral, symmetric, patchy, or confluent opacities are typically seen. The opacities are usually more pronounced in the perihilar and lower lung zones.
Gross Findings
The buildup of surfactant-rich material in the alveoli may cause the lungs to seem diffusely larger and heavier than usual.
Depending on the extent of surfactant buildup and related alterations, the afflicted lung tissue may be light, pinkish-Gray, or yellowish in color.
The process of consolidation is the accumulation of proteinaceous material in the alveolar gaps. It lowers air content and destroys the natural architecture of the lung.
Impaired secretion clearance and related inflammation can cause bronchi and bronchioles to appear dilated or enlarged.
Histological Observations
Alveoli filled with eosinophilic, periodic acid-Schiff (PAS)-positive material are visible under a microscope.
This substance is a representation of the aberrant build-up of lipids, surfactant proteins, and cell debris in the alveolar gaps.
Under a microscope, the deposited surfactant material frequently looks granular or finely vacuolated, giving the alveolar gaps a frothy appearance.
Foamy macrophages engorged with accumulated surfactant material may be found in alveolar spaces. These macrophages are involved in the PAS-positive staining that PAP exhibits.
Microscopic examination may indicate interstitial thickening and fibrosis, indicating chronic inflammation and tissue remodeling, in addition to alveolar involvement.
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Diffuse Alveolar Hemorrhage (DAH): DAH presents with similar clinical features, including dyspnea, cough, and hemoptysis. Radiological findings may include patchy or diffuse ground-glass opacities and consolidations. The diagnosis is confirmed by the presence of hemosiderin-laden macrophages in bronchoalveolar lavage fluid or lung biopsy specimens.
Organizing Pneumonia (OP): OP can mimic PAP clinically and radiologically, with symptoms such as cough, dyspnea, and bilateral ground-glass opacities on imaging. The presence of fibroblastic plugs within the alveolar spaces on histopathology is characteristic of OP.
Interstitial Lung Diseases (ILDs): Various ILDs, such as nonspecific interstitial pneumonia (NSIP), can present with similar symptoms and radiological findings as PAP.
Bronchoalveolar Carcinoma (BAC): BAC can present with diffuse infiltrates and ground-glass opacities on imaging, similar to PAP. Histologically, BAC demonstrates malignant cells within the alveolar spaces, which may mimic the appearance of surfactant-rich material seen in PAP.
Laboratory Studies
Immunohistochemistry
Surfactant proteins, such as surfactant protein A (SP-A) and surfactant protein D (SP-D), are essential components of pulmonary surfactant. Immunohistochemistry can demonstrate the presence of these surfactant proteins within the accumulated material in PAP.
Cytokeratins are intermediate filament proteins typically expressed in epithelial cells. In PAP, immunohistochemistry for cytokeratins may be used to demonstrate the presence of epithelial cells within the alveolar spaces, often associated with foamy macrophages.
CD68 is a marker commonly used to identify macrophages. In PAP, CD68 immunohistochemistry can demonstrate the presence of foamy macrophages within the alveolar spaces, reflecting their role in engulfing and processing the accumulated surfactant material.
While not a specific immunohistochemical marker, PAS staining is commonly used to highlight the presence of polysaccharides, glycoproteins, and glycolipids within tissues. PAS staining is often positive in PAP due to the carbohydrate-rich nature of surfactant proteins.
»
Home » CAD » Pathology of Pulmonary Alveolar Proteinosis
Pathology of Pulmonary Alveolar Proteinosis
Updated :
July 25, 2024
Interpretation
The uncommon lung condition known as pulmonary alveolar proteinosis (PAP) is characterized by the build-up of aberrant lipids and surfactant proteins alveoli. In tiny lungs air sacs, the gas exchange takes place.
Damage to the alveolar walls and adjacent tissues results from the excess surfactant accumulation causing an inflammatory response within the alveoli.
Gas exchange is hampered in PAP due to an aberrant buildup of surfactant in the alveoli.
With an approximate yearly incidence of less than 1 case per million people, PAP is regarded as a rare disease.
While PAP can occur anyone at any age, most cases are identified in people between the ages of 20 and 50.
PAP does not seem to have a substantial preference for either gender, affecting both sexes equally.
Location
As a result of the excess surfactant material filling the alveoli, less room is available for gas exchange and air is displaced. This filling causes blood oxygenation to be reduced, which can result in respiratory symptoms as coughing and dyspnea.
Within the alveoli, the accumulation of surfactant causes an inflammatory reaction. Inflammation can worsen gas exchange and is a contributing factor to lung damage.
Prolonged surfactant buildup can cause structural alterations in the alveoli, such as fibrosis and thickening of the alveolar wall. These alterations worsen lung function and add to the disease’s progressive character.
PAP that is categorized as autoimmune PAP accounts for the majority of instances. The immune system malfunction mainly involving lung macrophages is the root cause of this subtype. Surfactant accumulates in the alveoli of patients with autoimmune PAP due to insufficient clearance caused by malfunctioning or impaired macrophages.
A cytokine called granulocyte-macrophage colony-stimulating factor (GM-CSF) is essential for controlling surfactant clearance and alveolar macrophage activity.
Alveolar macrophage activity and surfactant clearance can be negatively impacted by autoantibodies against GM-CSF or mutations in genes encoding GM-CSF receptor components. These disruptions of normal signalling pathways can also occur.
Prognosis and Predictive Factors
Autoimmune PAP tends to have a better prognosis compared to secondary PAP, as autoimmune PAP is typically more responsive to treatment.
Secondary PAP, which occurs in the context of other underlying conditions, may have a less favorable prognosis, particularly if the underlying condition is severe or difficult to treat.
The severity of symptoms at the time of diagnosis can influence prognosis.
Imaging features such as the extent of lung involvement, presence of consolidations, and degree of ground-glass opacities may provide prognostic information.
Elevated levels of anti-GM-CSF antibodies or other serum biomarkers may be associated with more severe disease and poorer prognosis in autoimmune PAP.
Histopathological features observed on lung biopsy, such as the degree of inflammation, fibrosis, and alveolar damage, may provide insights into disease severity and prognosis.
Clinical Features and Imaging
Progressive exertional dyspnea is a frequently encountered sign of postural hypoxia. As the condition progresses, patients may experience breathing difficulties when exercising or even when they are at rest.
Another typical symptom is a persistent cough that frequently produces thick, viscous sputum. PAP patients usually complain of exhaustion and a reduced capacity for activity because of their compromised lung health.
Because of hypoxemia, cyanosis a bluish staining of the skin and mucous membranes may be seen in the disease’s later stages.
Severe PAP episodes may result in respiratory failure necessitating mechanical ventilation or further oxygen therapy.
Imaging Findings:
Bilateral, symmetric, patchy, or confluent opacities are typically seen. The opacities are usually more pronounced in the perihilar and lower lung zones.
Gross Findings
The buildup of surfactant-rich material in the alveoli may cause the lungs to seem diffusely larger and heavier than usual.
Depending on the extent of surfactant buildup and related alterations, the afflicted lung tissue may be light, pinkish-Gray, or yellowish in color.
The process of consolidation is the accumulation of proteinaceous material in the alveolar gaps. It lowers air content and destroys the natural architecture of the lung.
Impaired secretion clearance and related inflammation can cause bronchi and bronchioles to appear dilated or enlarged.
Histological Observations
Alveoli filled with eosinophilic, periodic acid-Schiff (PAS)-positive material are visible under a microscope.
This substance is a representation of the aberrant build-up of lipids, surfactant proteins, and cell debris in the alveolar gaps.
Under a microscope, the deposited surfactant material frequently looks granular or finely vacuolated, giving the alveolar gaps a frothy appearance.
Foamy macrophages engorged with accumulated surfactant material may be found in alveolar spaces. These macrophages are involved in the PAS-positive staining that PAP exhibits.
Microscopic examination may indicate interstitial thickening and fibrosis, indicating chronic inflammation and tissue remodeling, in addition to alveolar involvement.
Diffuse Alveolar Hemorrhage (DAH): DAH presents with similar clinical features, including dyspnea, cough, and hemoptysis. Radiological findings may include patchy or diffuse ground-glass opacities and consolidations. The diagnosis is confirmed by the presence of hemosiderin-laden macrophages in bronchoalveolar lavage fluid or lung biopsy specimens.
Organizing Pneumonia (OP): OP can mimic PAP clinically and radiologically, with symptoms such as cough, dyspnea, and bilateral ground-glass opacities on imaging. The presence of fibroblastic plugs within the alveolar spaces on histopathology is characteristic of OP.
Interstitial Lung Diseases (ILDs): Various ILDs, such as nonspecific interstitial pneumonia (NSIP), can present with similar symptoms and radiological findings as PAP.
Bronchoalveolar Carcinoma (BAC): BAC can present with diffuse infiltrates and ground-glass opacities on imaging, similar to PAP. Histologically, BAC demonstrates malignant cells within the alveolar spaces, which may mimic the appearance of surfactant-rich material seen in PAP.
Immunohistochemistry
Surfactant proteins, such as surfactant protein A (SP-A) and surfactant protein D (SP-D), are essential components of pulmonary surfactant. Immunohistochemistry can demonstrate the presence of these surfactant proteins within the accumulated material in PAP.
Cytokeratins are intermediate filament proteins typically expressed in epithelial cells. In PAP, immunohistochemistry for cytokeratins may be used to demonstrate the presence of epithelial cells within the alveolar spaces, often associated with foamy macrophages.
CD68 is a marker commonly used to identify macrophages. In PAP, CD68 immunohistochemistry can demonstrate the presence of foamy macrophages within the alveolar spaces, reflecting their role in engulfing and processing the accumulated surfactant material.
While not a specific immunohistochemical marker, PAS staining is commonly used to highlight the presence of polysaccharides, glycoproteins, and glycolipids within tissues. PAS staining is often positive in PAP due to the carbohydrate-rich nature of surfactant proteins.
The uncommon lung condition known as pulmonary alveolar proteinosis (PAP) is characterized by the build-up of aberrant lipids and surfactant proteins alveoli. In tiny lungs air sacs, the gas exchange takes place.
Damage to the alveolar walls and adjacent tissues results from the excess surfactant accumulation causing an inflammatory response within the alveoli.
Gas exchange is hampered in PAP due to an aberrant buildup of surfactant in the alveoli.
With an approximate yearly incidence of less than 1 case per million people, PAP is regarded as a rare disease.
While PAP can occur anyone at any age, most cases are identified in people between the ages of 20 and 50.
PAP does not seem to have a substantial preference for either gender, affecting both sexes equally.
Location
As a result of the excess surfactant material filling the alveoli, less room is available for gas exchange and air is displaced. This filling causes blood oxygenation to be reduced, which can result in respiratory symptoms as coughing and dyspnea.
Within the alveoli, the accumulation of surfactant causes an inflammatory reaction. Inflammation can worsen gas exchange and is a contributing factor to lung damage.
Prolonged surfactant buildup can cause structural alterations in the alveoli, such as fibrosis and thickening of the alveolar wall. These alterations worsen lung function and add to the disease’s progressive character.
PAP that is categorized as autoimmune PAP accounts for the majority of instances. The immune system malfunction mainly involving lung macrophages is the root cause of this subtype. Surfactant accumulates in the alveoli of patients with autoimmune PAP due to insufficient clearance caused by malfunctioning or impaired macrophages.
A cytokine called granulocyte-macrophage colony-stimulating factor (GM-CSF) is essential for controlling surfactant clearance and alveolar macrophage activity.
Alveolar macrophage activity and surfactant clearance can be negatively impacted by autoantibodies against GM-CSF or mutations in genes encoding GM-CSF receptor components. These disruptions of normal signalling pathways can also occur.
Prognosis and Predictive Factors
Autoimmune PAP tends to have a better prognosis compared to secondary PAP, as autoimmune PAP is typically more responsive to treatment.
Secondary PAP, which occurs in the context of other underlying conditions, may have a less favorable prognosis, particularly if the underlying condition is severe or difficult to treat.
The severity of symptoms at the time of diagnosis can influence prognosis.
Imaging features such as the extent of lung involvement, presence of consolidations, and degree of ground-glass opacities may provide prognostic information.
Elevated levels of anti-GM-CSF antibodies or other serum biomarkers may be associated with more severe disease and poorer prognosis in autoimmune PAP.
Histopathological features observed on lung biopsy, such as the degree of inflammation, fibrosis, and alveolar damage, may provide insights into disease severity and prognosis.
Clinical Features and Imaging
Progressive exertional dyspnea is a frequently encountered sign of postural hypoxia. As the condition progresses, patients may experience breathing difficulties when exercising or even when they are at rest.
Another typical symptom is a persistent cough that frequently produces thick, viscous sputum. PAP patients usually complain of exhaustion and a reduced capacity for activity because of their compromised lung health.
Because of hypoxemia, cyanosis a bluish staining of the skin and mucous membranes may be seen in the disease’s later stages.
Severe PAP episodes may result in respiratory failure necessitating mechanical ventilation or further oxygen therapy.
Imaging Findings:
Bilateral, symmetric, patchy, or confluent opacities are typically seen. The opacities are usually more pronounced in the perihilar and lower lung zones.
Gross Findings
The buildup of surfactant-rich material in the alveoli may cause the lungs to seem diffusely larger and heavier than usual.
Depending on the extent of surfactant buildup and related alterations, the afflicted lung tissue may be light, pinkish-Gray, or yellowish in color.
The process of consolidation is the accumulation of proteinaceous material in the alveolar gaps. It lowers air content and destroys the natural architecture of the lung.
Impaired secretion clearance and related inflammation can cause bronchi and bronchioles to appear dilated or enlarged.
Histological Observations
Alveoli filled with eosinophilic, periodic acid-Schiff (PAS)-positive material are visible under a microscope.
This substance is a representation of the aberrant build-up of lipids, surfactant proteins, and cell debris in the alveolar gaps.
Under a microscope, the deposited surfactant material frequently looks granular or finely vacuolated, giving the alveolar gaps a frothy appearance.
Foamy macrophages engorged with accumulated surfactant material may be found in alveolar spaces. These macrophages are involved in the PAS-positive staining that PAP exhibits.
Microscopic examination may indicate interstitial thickening and fibrosis, indicating chronic inflammation and tissue remodeling, in addition to alveolar involvement.
Diffuse Alveolar Hemorrhage (DAH): DAH presents with similar clinical features, including dyspnea, cough, and hemoptysis. Radiological findings may include patchy or diffuse ground-glass opacities and consolidations. The diagnosis is confirmed by the presence of hemosiderin-laden macrophages in bronchoalveolar lavage fluid or lung biopsy specimens.
Organizing Pneumonia (OP): OP can mimic PAP clinically and radiologically, with symptoms such as cough, dyspnea, and bilateral ground-glass opacities on imaging. The presence of fibroblastic plugs within the alveolar spaces on histopathology is characteristic of OP.
Interstitial Lung Diseases (ILDs): Various ILDs, such as nonspecific interstitial pneumonia (NSIP), can present with similar symptoms and radiological findings as PAP.
Bronchoalveolar Carcinoma (BAC): BAC can present with diffuse infiltrates and ground-glass opacities on imaging, similar to PAP. Histologically, BAC demonstrates malignant cells within the alveolar spaces, which may mimic the appearance of surfactant-rich material seen in PAP.
Immunohistochemistry
Surfactant proteins, such as surfactant protein A (SP-A) and surfactant protein D (SP-D), are essential components of pulmonary surfactant. Immunohistochemistry can demonstrate the presence of these surfactant proteins within the accumulated material in PAP.
Cytokeratins are intermediate filament proteins typically expressed in epithelial cells. In PAP, immunohistochemistry for cytokeratins may be used to demonstrate the presence of epithelial cells within the alveolar spaces, often associated with foamy macrophages.
CD68 is a marker commonly used to identify macrophages. In PAP, CD68 immunohistochemistry can demonstrate the presence of foamy macrophages within the alveolar spaces, reflecting their role in engulfing and processing the accumulated surfactant material.
While not a specific immunohistochemical marker, PAS staining is commonly used to highlight the presence of polysaccharides, glycoproteins, and glycolipids within tissues. PAS staining is often positive in PAP due to the carbohydrate-rich nature of surfactant proteins.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
